Director, Investor Relations

Zealand Pharma A/S; Denmark; Presencial; DKK 1.200.000 - 1.800.000; Jornada completa

Descripción de la vacante

Zealand Pharma A/S in Copenhagen, Denmark, is seeking a Director of Investor Relations to articulate the company’s equity story to the European investment community and collaborate with senior leadership. You translate complex science and clinical progress into clear financial narratives for shareholders and analysts, while shaping strategic communication and investor engagement.

You will build relationships with institutional investors, plan roadshows, coordinate earnings communications, and

Formación

• Significant experience in investor relations and corporate communications in biotech/pharma or healthcare.
• Strong understanding of drug development and biotech valuation drivers, plus knowledge of financial markets and disclosure requirements.
• Proven track record building relationships with institutional investors, sell-side analysts, and the European investment community.

Responsabilidades

• Strengthen and expand relationships with European institutional investors, sell-side analysts, and other capital market stakeholders, serving as a primary contact for investor inquiries
• Support the development and execution of the IR strategy and equity story in alignment with the Head of Investor Relations and senior leadership
• Plan and lead European roadshows, investor meetings, conferences, and capital markets events, as well as quarterly earnings communications
• Prepare financial results communications, earnings releases, investor presentations, scripts, Q&A materials, and annual/interim report content
• Monitor market trends, investor sentiment, and shareholder composition in Europe and provide insights to leadership
• Contribute to corporate communications, including press releases, media relations, and social media content, ensuring compliant messaging with Legal, Finance, and Corporate Communications

Conocimientos

Investor relations

Corporate communications

Equity research

Investment banking

Stakeholder management

English communication

Educación

University degree in finance, economics, communications, business, life sciences, or related field

MBA (advantageous)

Descripción del empleo

Does it excite you to work with shaping the equity story of a peptide-based biotech company and strengthening relationships with investors and analysts across Europe, and do you have experience with investor relations and corporate communications in biotech or pharma? If this sounds like you, and you are ready to take on a broad area of responsibilities, then you could be our new colleague. Your new position As Director of Investor Relations, you will be a key voice of the company towards the global investment community, working closely with the Vice President, Head of Investor Relations. A central focus of the position is to enhance and grow relationships with analysts and investors in Europe. You will translate complex science, clinical progress, and strategy into a clear and credible narrative for shareholders, prospective investors, analysts, and the broader financial community. The position combines strategic communication, close collaboration with senior leadership, and direct exposure to the capital markets at an exciting stage of the company’s development.

We offer exciting responsibilities:

• Strengthen and expand relationships with European institutional investors, sell-side analysts, and other capital market stakeholders, serving as a primary point of contact for investor inquiries
• Support the development and execution of the investor relations strategy and equity story in close alignment with the Head of Investor Relations, senior leadership, and the company’s financial and strategic goals
• Work together with IR Coordinator to plan and lead European roadshows, investor meetings, conferences, and capital markets events, as well as quarterly earnings communications
• Prepare financial results communications, earnings releases, investor presentations, scripts, Q&A materials, and annual and interim report content
• Monitor and analyze market trends, competitive intelligence, investor sentiment, and shareholder composition, particularly in Europe, and provide insights and recommendations to leadership
• Contribute to corporate communications, including press releases, media relations, and social media content, and safeguard consistent corporate messaging across channels, while ensuring compliance with applicable disclosure and market regulations in collaboration with Legal, Finance, and Corporate Communications

Your profile

You are a credible and confident communicator who builds trust easily with both scientific and financial audiences. You are strategic and analytical, with strong financial acumen and sound judgment when handling sensitive and market-moving information. You are highly organized, detail-oriented, and comfortable managing multiple projects at pace. You are a natural collaborator who works effectively across functions.

• Significant experience in investor relations, corporate communications, equity research, investment banking, or a related capital markets role, within biotech, pharma, or healthcare
• Strong understanding of drug development, clinical data, and biotech valuation drivers, as well as in-depth knowledge of financial markets and listed-company disclosure and reporting requirements
• Proven track record of building and maintaining relationships with institutional investors, sell-side analysts, and the media, ideally with an established network in the European investment community
• Strong analytical skills with the ability to interpret financial data and industry trends Ability to collaborate across functions and influence stakeholders at all levels, including senior leadership, combined with excellent written and verbal communication skills in English University degree in finance, economics, communications, business, life sciences, or a related field; an MBA is a plus

Your new team

The position reports to the Vice President, Head of Investor Relations, and is part of the Investor Relations team that reports to the CFO. The team includes an Investor Relation coordinator and we work very closely with Corporate Communications.

Let’s bond and be bold

We have a unique culture, characterized by excellent teamwork and strong engagement across the organization. And we want you to help us strengthen this culture. Making bonds is at the core of everything we do. From discovering and developing the best new drugs for metabolic health for patients, to engaging with our partners or connecting with each other. We bond through curiosity and playfulness as a team, allowing ourselves to challenge common thinking and drive future innovation. Join us and let’s bond and be bold.

We are committed to an inclusive recruitment process and welcome applications from all job applicants.

About Zealand Pharma A/S

A/S Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data-driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health.

To date, more than ten Zealand Pharma-invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization.

Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Boston, Massachusetts. Learn more at www.zealandpharma.com.

Since our founding in 1998, Zealand Pharma has built a core expertise in the discovery, design, and development of therapeutic peptides. This expertise has led to an R&D pipeline of innovative investigational candidates designed to address a broad range of disease areas.

We have four therapeutic focus areas: obesity, rare diseases, chronic inflammation, and type 1 diabetes.

In obesity, our peptide capabilities place us in a unique position to address a vast global health challenge and positively impact hundreds of millions of lives. Within rare diseases, we have a long-standing commitment to deliver new treatments to patients living with congenital hyperinsulinism and short bowel syndrome. For chronic inflammatory diseases, we are progressing peptide programs focused on high-profile targets shown to be difficult to address with small molecules and antibodies. For type 1 diabetes, we aspire to change the management of this disease. Our strategy is to pursue global co-development and commercialization partnerships that complement and extend our capabilities across the value chain to deliver new peptide therapies to people who need them.